Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N7N8 | ISIN: KYG4818G1010 | Ticker-Symbol: 6IB
Stuttgart
27.06.25 | 08:07
8,050 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOVENT BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
INNOVENT BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,2008,60022:27
8,2008,45022:00

Aktuelle News zur INNOVENT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18:10With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs6
13:43Innovent's Mazdutide receives approval for chronic weight management in China1
13:00Innovent Biologics' Mazdutide Gets China Approval For Chronic Weight Management205BEIJING (dpa-AFX) - Innovent Biologics, Inc. (IVBXF.OB) announced Friday that China's National Medical Products Administration or NMPA has approved mazdutide for chronic weight management in...
► Artikel lesen
11:47INNOVENT BIO's Weight Loss Drug Approved For Chronic Weight Mgmt1
10:30INNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - FIRST DUAL GCG/GLP-1 RECEPTOR AGONIST MAZDUTIDE RECEIVED APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ...-
10:17CN NMPA Approves Innovent Biologics' GLP-1 Weight Loss Drug for Marketing1
DoINNOVENT BIO Craters 4%+ in Morning Session on 4.9% Discount to Raise $4.27B in Shr Placement3
DoINNOVENT BIO Raises Net Proceeds of $4.27B in Shr Placement at 4.9% Discount2
INNOVENT BIOLOGICS Aktie jetzt für 0€ handeln
DoINNOVENT BIO (01801): PLACING OF NEW SHARES UNDER GENERAL MANDATE1
MiINNOVENT BIO (01801): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 20253
MoCMBI Recommends 3 3SBIO/BEIGENE/INNOVENT BIO/GIANT BIOGENE; CN Pharmas to Face ST Pullback Pressure5
19.06.UOB Kay Hian: Industry Enters New Phase of Accelerated Growth; Top Picks INNOVENT BIO/HANSOH PHARMA/SINO BIOPHARM3
16.06.Innovent Biologics: Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China80SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
09.06.JPM Raises INNOVENT BIO's TP to HKD84, Reiterating Overweight Rating2
06.06.G Sachs Elevates INNOVENT BIO TP to $74.95, Rating Buy12
05.06.Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance-
05.06.BOCI Elevates INNOVENT BIO TP to $82, Keeps Rating at Buy3
05.06.New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN1
05.06.HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted1
05.06.Innovent's IBI363 Receives Second NMPA Breakthrough Therapy Designation For Immuno-resistant SqNSCLC367BEIJING (dpa-AFX) - Innovent Biologics Inc. (IVBXF.OB) announced Wednesday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a...
► Artikel lesen
Weiter >>
88 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1